Axillary lymphadenopathy following bivalent COVID-19 booster vaccination
With the recent FDA emergency use authorizations of the bivalent Pfizer-BioNTech and Moderna COVID-19 vaccines, in conjunction with documented lymphadenopathy in clinical trials, vaccine history should continue to be considered when encountering unilateral axillary lymphadenopathy. With the rise of the Omicron subvariants came a reduced effectiveness of the monovalent COVID-19 vaccines, leading to the development of the bivalent COVID-19 vaccines (Original and Omicron B.4/B.5) [1]. The Moderna bivalent booster contains 25 μg of the nucleoside-modified mRNA that was used in the original vaccine that encodes the “prefusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Wuhan-Hu-1 strain” and 25 μg of mRNA that encodes “the pre-fusion stabilized S-protein of the SARS-CoV-2 Omicron variant lineages BA.4 and BA.5”.
Source: Clinical Imaging - Category: Radiology Authors: Elizabeth G. Lane, Kemi Babagbemi, Eralda Mema, Katerina Dodelzon Tags: Breast imaging Source Type: research
More News: Clinical Trials | Covid Vaccine | COVID-19 | Emergency Medicine | Pfizer | Radiology | SARS | Vaccines